All episodes
How Are Oncologists Managing Amivantamab Plus Lazertinib in EGFR- Mutant NSCLC?
Who Still Needs Monotherapy in EGFR- Mutant NSCLC
Is It Time for a New Type of Cancer Physician?
What the “Tsunami” of Cancer Survivors Means for Oncologists
“Sobering” Takeaway From ASCO 2026: Concerns About Clinical Trial Participation
“A Lot More Asymptomatic Cancer Out There”: Major MCED Trial Hints at Complicated Future
“The Ever-Shifting and Chaotic” State of CLL Care: What New Data Mean for Practice
How “Drastically Better” Treatments for Some Colorectal Cancers Are Changing Care
“Not a Straightforward Decision”: What to Do While Waiting on a Practice Change in Breast Cancer Care
New Targeted Therapies Make Breast Cancer Treatment Decisions “a Bit of a Moving Target”
Advances in ESR1-Mutated Breast Cancer Care Lead to “Complex Situation” in Clinic
Tackling “the Biggest Question That Everyone Is Asking” in Breast Cancer Care
Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC
“Where the Real Answer Lies”: How CNS Disease Influences EGFR-Mutated NSCLC Treatment Decisions
Second-Line Options in EGFR-Mutated NSCLC: What’s the Right Sequence?
“Is the Juice Worth the Squeeze?”: Treatment Intensification for Advanced EGFRm NSCLC
As Terminal Patients Live Longer, How Can Oncologists Help Them Cope With Uncertainty?
Should Patients With Cancer Receive mRNA Vaccines Alongside Immunotherapy?
Big News From ESMO 2025 Changes Practice in Bladder Cancer
Big Changes in AML Care as Targeted Therapy Options Expand
Artificial Sweetener May Impair Cancer Immunotherapy, Raising Broader Questions
“Massive Advance” Changes the Chessboard in EGFR-Mutated Metastatic NSCLC
Are Oral SERDs About to Transform Breast Cancer Care?
Game-Changers and Paradigm Shifts: ASCO 2025 Data Shake Up Breast Cancer Care
Practice-Changing Data in Colorectal Cancer Lead to Broader Questions in Oncology
Oncologist Faculty Burnout Caused by “Unrealistic” Expectations, Says ASCO CEO
After Years of Inactivity, “Dizzying” Changes Hit Bladder Cancer Care
Practice Changing or “Practice Confounding”? Pivotal Breast Cancer Data Raise Big Questions
NCCN CEO Discusses Guideline Updates, Other Key Initiatives
Former National Cancer Institute Director Discusses the Future of Cancer Care
Game-Changing Blood Cancer News at ASCO 2025: Rusfertide Shows Strong Benefit in Polycythemia Vera
Getting Americans to Support Cancer Research May Take a New Message, Oncology Leader Says
“Important Milestone”: Perioperative Durvalumab Improves Event-Free Survival in Gastric Cancer
What Does the Biggest News in Breast Cancer From ASCO 2025 Mean for Practice Right Now?
Practice-Changing “Inflection Point” Coming in ESR1-Positive Breast Cancer Care?
When ESR1 Mutations Arise in Breast Cancer Patients With PIK3CA Mutations: What Next?
How “Remarkable Change” in EGFR-Mutated NSCLC Care Is Making a Difference for Patients
Oncologists Urged to Discuss Fertility With Patients, as ASCO Updates Guidelines
“Second-Line ER-Positive Breast Cancer Has Just Become Very Complicated”
Will Generational Divide Among Oncologists Affect How AI Changes Cancer Care?
“Time to Move On”: How Targeted Therapies Are Transforming AML Care
ASCO President Speaks Out on “Huge Problem” of Oncologist Burnout
Oncologists Overtreat Patients at End of Life
FDA Approvals Change Practice for Metastatic Breast Cancer With PIK3CA Mutations
To Help Oncologists’ Burnout, Should Primary Care Take on More Burden?
Choosing Between an “Old Friend” and New Ones in EGFR-Mutated Metastatic NSCLC
Privatization of Cancer Clinical Research Raises Concerns for Practice
What 3 Big Trials Mean for Breast Cancer Practice
“Confusing for All of Us”: Questions Arise Over ADCs, HER2 in Metastatic Breast Cancer
”Where Do We Go From Here?” Targeted Therapies Lead to Challenging Choices in Breast Cancer
After Practice Change in Unresectable Stage III NSCLC, Questions Remain
What ”Incredibly Dramatic” Data on Osimertinib in NSCLC Mean for Practice
“Smart Bombs” Upend Breast Cancer Care: What Oncologists May Not Know About Antibody-Drug Conjugates
Oncology Must Do More for Long-Term Cancer Survivors, Expert Says
“A Good, Peaceful Death” From Cancer: Oncologists Must Be Part of “National Dialogue”
FDA Approvals in Relapsed/Refractory CLL Set up ”Difficult Choice”
Oncologists Struggling With Cancer Deaths Among Millennial Patients
Top Lung Cancer Data From ASCO 2024 Should Change Practice “Immediately,” Experts Agree
What Were the Biggest Data at ASCO 2024 in Kidney Cancer?
What New “Elephant in the Room” Means for Bladder Cancer Care
Immunotherapy in “Hardest Stage” of NSCLC: Putting Recent Advances Into Practice
”We’re Past the Inflection Point,” as ”Massive Change” Hits Breast Cancer Care
To Get Better Cancer Drugs Faster, Is It Time for an “International FDA”?
”Very Important” Myeloma Data: ASCO Highlights, Smoldering Challenges, and More
Durvalumab’s Benefit in SCLC ”Beyond What We Might Have Expected”
New Standard of Care in Melanoma? Neoadjuvant Immunotherapy Offers ”Fantastic” Potential, Expert Says
Should All Breast Cancer Patients Get T-DXd? ”Results of DESTINY-Breast06 Do Suggest That”
Oncologist Shortage “Has Gotten to the Crisis Level”
“Monster Improvements” in CLL Care Prompt Questions About BTK Inhibitor Use
“Better to Have Choices”: How New Data Transform EGFR-Mutated NSCLC Care
Practice-Changing Data Introduce “Whole New Challenge” in Prostate Cancer
FDA Approval for TIL Therapy “Real Milestone” That Has Been “Long Time Coming”
From “Fairytale” to Reality? Paradigm Shift in Bladder Cancer Care
FDA Approvals, Pivotal Trial Data Change Approach to Breast Cancer Progression
Controversies, Difficult Questions Arise in NSCLC Amid New Data
What FDA Approval of Belzutifan Means for Kidney Cancer Care
Despite Lack of Head-to-Head Trials, Practice Patterns Shifting in Breast Cancer
Which FDA Approvals, Other Advances Changed ER-Positive Breast Cancer Care in 2023?
“New Disruptor” in Prostate Cancer: PSMA PET and Other Treatment Advances
Practice-Changing Results in Prostate Cancer, as Enzalutamide Regimens Show Strong Benefit
ER-Positive Breast Cancer Advances and Other Eagerly Anticipated Data at SABCS 2023
Inside ODAC’s Vote on Sotorasib in Advanced and Metastatic NSCLC: Lessons Learned
First-Line Osimertinib Plus Chemo in NSCLC: How to Weigh Toxicity vs. Efficacy
What Recent “Outstanding Results” in MCL Mean for Practice
The Quest to Cure CLL: “Remarkable” Results With New Strategy
Which Data From the 2023 World Conference on Lung Cancer Are Most Likely to Change Practice?
“Really Impactful” New Guidelines for Stage IV NSCLC With Driver Alterations
More “Cage Rattling,” Less Talking: Susan Love’s Lessons for Oncologists
Will HER3 Targeting Change Breast Cancer Care?
“Practice-Expanding” Data on Adjuvant Osimertinib in NSCLC: Steps to Take Now
“Don’t Just Throw Drugs Together”: How to Best Approach ESR1 Mutations in Breast Cancer
mRNA Cancer Vaccines: When to Expect FDA Approval, and What’s Next?
“Major Wins” in Lung Cancer Treatment: How “Explosion of Data” Is Changing Practice
“Great Therapies for All-Comers” in CLL: How Can Oncologists “Pick and Choose?”
Pragmatica-Lung Tests a Treatment and a New Approach to Trials
The Best First Step in Metastatic NSCLC Care
Neo- and Adjuvant Treatments Are Changing Care in Early NSCLC
NALIRIFOX Changes Care in Pancreatic Cancer: Here’s How
Matching Breast Cancer Patients to Therapies: Here’s How
Myelofibrosis Remains Tough to Treat, But New Drugs Are Paving the Way